Sundia’s SARS-CoV-2 3CLpro assay is ready to meet the challenges of COVID-19 pandemic

Sundia's Biology team completes SARS-CoV-2 3CLPro screening platform to hasten anti-COVID-19 drug development in response to the 2019-nCoV pandemic.
April 18, 2020

BioDuro Breaks Ground on 300,000 sq ft Facility in Jiangsu China

SAN DIEGO, April 17, 2020 – The groundbreaking ceremony for BioDuro’s China Innovative Drug R&D Center was held in Wuxi Huishan Life Science Park in Jiangsu, China. The site is BioDuro’s 4th glo
April 17, 2020

BioDuro Strengthens Senior Leadership of Global CMC Solutions Business Unit

SAN DIEGO, April 1, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the appointment of two senior leadership positions to the Global CMC Solutions bus
April 01, 2020

Congratulations to HitGen for NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial

HitGen's HG030, an NTRK/ROS1 inhibitor, approved for clinical trial—a milestone for Shanghai-based biotech, enhancing treatment options.
April 01, 2020

BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic

SAN DIEGO, March 26, 2020 – BioDuro LLC, a leading global life sciences contract research and development organization announced today that it has initiated a COVID-19 nanobody therapeutic program, le
March 26, 2020
Total 84 12...78910111213...1617
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all